The application of the proteasome inhibitor MG-132 on USP7 knockdown CRC cells further revealed that the reduction in YY1 protein expression resulting from USP7 knockdown can be partially reversed by inhibiting the proteasome degradation pathway (Fig. 2I, J). This evidence concerns the gene USP7 and colorectal carcinoma.